ADIENNE is an integrated biopharmaceutical group of companies based in Lugano, Switzerland, with a proprietary portfolio of orphan-designated marketed medicinal product, clinical and preclinical product candidates focusing on critical conditions of high unmet medical needs. ADIENNE provides drug medicine services. Their services include focusing on orphan drug development for the treatment of hematological and immunological diseases, drug design and repositioning, virtual screening, combinatorial chemistry, molecular dynamics, and enzyme design.

Tags

Urogenital Diseases

Other Diseases

Hemic and Lymphatic Diseases

Small molecule drug

Monoclonal antibody

Disease domain score

A glimpse into the focused therapeutic areas

Technology Platform

Most used technologies in drug development

Targets

Most frequently developed targets

Disease Domain	Count

Hemic and Lymphatic Diseases	2
Endocrinology and Metabolic Disease	1
Immune System Diseases	1
Neoplasms	1

Top 5 Drug Type	Count

Small molecule drug	1
Monoclonal antibody	1

Top 5 Target	Count

C5AR1(C5a anaphylatoxin chemotactic receptor)	1
DNA	1

Drugs associated with Adienne SA

Thiotepa

Target

DNA

Mechanism

DNA inhibitors [+1]

Active Org.

Sumitomo Pharma Co., Ltd. [+9]

Originator Org.

Wyeth Holdings LLC

Active Indication

Lymphoma [+13]

Inactive Indication-

Drug Highest PhaseApproved

First Approval Ctry. / Loc.

First Approval Date09 Mar 1959

SAND-5

Target

C5AR1

Mechanism

C5AR1 antagonists

Active Org.

Adienne SA

Originator Org.

Adienne SA

Active Indication

Hemolytic-Uremic Syndrome

Inactive Indication-

Drug Highest PhasePreclinical

First Approval Ctry. / Loc.-

First Approval Date-

Begelomab

Target

DPP-4

Mechanism

DPP-4 inhibitors

Active Org.-

Originator Org.

Adienne SA

Active Indication-

Inactive Indication

Graft vs Host Disease [+1]

Drug Highest PhaseDiscontinued

First Approval Ctry. / Loc.-

First Approval Date-

Clinical Trials associated with Adienne SA

EUCTR2021-000898-83-IT / Unknown statusPhase 2

A phase II, randomized, double-blind, placebo-controlled, two-period, crossover trial to assess the efficacy and safety of begelomab in combination with standard steroid and/or immunosuppressant therapy in the treatment of patients with dermatomyositis - ADN016

Start Date10 Nov 2021

Sponsor / Collaborator

Adienne SA

NCT04217278 / Active, not recruitingPhase 2/3IIT

An International Randomised Clinical Trial of Therapeutic Interventions to Assess the Effects on Outcome in Adults With Acute Myeloid Leukaemia and High Risk Myelodysplasia Undergoing Allogeneic Stem Cell Transplantation.

Treatment options for older adults with Acute Myeloid Leukaemia (AML) and Myelodysplasia (MDS) are limited. Although stem cell transplantation remains one of the most effective treatments it is associated with severe side effects which have until recently prevented its use in older adults. In the last decade the use of reduced intensity transplants has allowed the extension of the potentially curative effect of transplantation to older patients in whom it was previously precluded. Although a major advance such transplants are associated with a high risk of disease relapse particularly in patients with high risk disease.
This study will evaluate new transplant strategies with the aim of improving the outcome of patients with AML and high risk MDS after stem cell transplantation. Three approaches to improve transplant outcome will be studied:
Comparing the new pre-transplant consolidation therapy vyxeos with the standard consolidation therapy (Randomisation 1 is now closed to recruitment).
Comparing new conditioning therapies in patients under the age of 55 years
Comparing new conditioning therapies in patients aged 55 and over
All patients will be followed up for a minimum of 2 years.

Start Date27 Jan 2020

Sponsor / Collaborator

University of Birmingham

[+2]

EUCTR2017-002715-34-IT / Not yet recruitingPhase 1/2

A Phase I/II, open label, dose escalation study to investigate the pharmacokinetics, pharmacodynamics, safety and clinical activity of begelomab as an initial treatment of acute Graft-versus-Host Disease in combination with standard steroid therapy

Start Date30 Jan 2018

Sponsor / Collaborator

Adienne SA

100 Clinical Results associated with Adienne SA

0 Patents (Medical) associated with Adienne SA

Literatures (Medical) associated with Adienne SA

CancersQ2 · MEDICINE

Targeting Chronic Myeloid Leukemia Stem/Progenitor Cells Using Venetoclax-Loaded Immunoliposome

Q2 · MEDICINE

ArticleOA

Author: Russo, Sabina ; Pregno, Patrizia ; Spinelli, Michela ; Iurlo, Alessandra ; Stagno, Fabio ; Bonifacio, Massimiliano ; Houshmand, Mohammad ; Martino, Bruno ; Galimberti, Sara ; Circosta, Paola ; Stefania, Rachele ; Cignetti, Alessandro ; Pungolino, Ester ; Fava, Carmen ; Saglio, Giuseppe ; Annunziata, Mario ; Garello, Francesca ; Gaidano, Valentina ; Binotto, Gianni ; Nikougoftar Zarif, Mahin ; Luciano, Luigia ; Specchia, Giorgina ; Bocchia, Monica ; Aime, Silvio

CML is a hematopoietic stem-cell disorder emanating from breakpoint cluster region/Abelson murine leukemia 1 (BCR/ABL) translocation. Introduction of different TKIs revolutionized treatment outcome in CML patients, but CML LSCs seem insensitive to TKIs and are detectable in newly diagnosed and resistant CML patients and in patients who discontinued therapy. It has been reported that CML LSCs aberrantly express some CD markers such as CD26 that can be used for the diagnosis and for targeting. In this study, we confirmed the presence of CD26+ CML LSCs in newly diagnosed and resistant CML patients. To selectively target CML LSCs/progenitor cells that express CD26 and to spare normal HSCs/progenitor cells, we designed a venetoclax-loaded immunoliposome (IL-VX). Our results showed that by using this system we could selectively target CD26+ cells while sparing CD26− cells. The efficiency of venetoclax in targeting CML LSCs has been reported and our system demonstrated a higher potency in cell death induction in comparison to free venetoclax. Meanwhile, treatment of patient samples with IL-VX significantly reduced CD26+ cells in both stem cells and progenitor cells population. In conclusion, this approach showed that selective elimination of CD26+ CML LSCs/progenitor cells can be obtained in vitro, which might allow in vivo reduction of side effects and attainment of treatment-free, long-lasting remission in CML patients.

Frontiers in ImmunologyQ2 · MEDICINE

Targeted Delivery of Neutralizing Anti-C5 Antibody to Renal Endothelium Prevents Complement-Dependent Tissue Damage

Q2 · MEDICINE

ArticleOA

Author: De Maso, Luca ; Di Naro, Antonio F ; Durigutto, Paolo ; Colombo, Federico ; Tedesco, Francesco ; Sblattero, Daniele ; Biffi, Stefania ; Macor, Paolo ; Baj, Gabriele ; Fischetti, Fabio ; Garrovo, Chiara

Complement activation is largely implicated in the pathogenesis of several clinical conditions and its therapeutic neutralization has proven effective in preventing tissue and organ damage. A problem that still needs to be solved in the therapeutic control of complement-mediated diseases is how to avoid side effects associated with chronic neutralization of the complement system, in particular, the increased risk of infections. We addressed this issue developing a strategy based on the preferential delivery of a C5 complement inhibitor to the organ involved in the pathologic process. To this end, we generated Ergidina, a neutralizing recombinant anti-C5 human antibody coupled with a cyclic-RGD peptide, with a distinctive homing property for ischemic endothelial cells and effective in controlling tissue damage in a rat model of renal ischemia/reperfusion injury (IRI). As a result of its preferential localization on renal endothelium, the molecule induced complete inhibition of complement activation at tissue level, and local protection from complement-mediated tissue damage without affecting circulating C5. The ex vivo binding of Ergidina to surgically removed kidney exposed to cold ischemia supports its therapeutic use to prevent posttransplant IRI leading to delay of graft function. Moreover, the finding that the ex vivo binding of Ergidina was not restricted to the kidney, but was also seen on ischemic heart, suggests that this RGD-targeted anti-C5 antibody may represent a useful tool to treat organs prior to transplantation. Based on this evidence, we propose preliminary data showing that Ergidina is a novel targeted drug to prevent complement activation on the endothelium of ischemic kidney.

News (Medical) associated with Adienne SA

24 Sep 2024

·www.businesswire.com

Launch of Aptadir Therapeutics With a Novel Class of RNA Inhibitors

MILAN--( BUSINESS WIRE )--Aptadir Therapeutics (Aptadir), a biotech company developing RNA inhibitor-based therapeutics for treating intractable cancers and genetic conditions, announces its launch and the appointment of Giovanni Amabile as Executive Chairman and acting CEO. Aptadir was founded by Dr Annalisa Di Ruscio and Dr Vittorio De Franciscis, both leaders in the field of RNA biology and DNA methylation, alongside Prof. Daniel Tenen, an expert in MDS and leukaemia, and Prof. Marcin Kortylewski, an expert in oligonucleotide immunotherapeutics. They are based at world class institutions: the Beth Israel Deaconess Medical Center of the Harvard Medical School, the Italian Research National Council, the Cancer Science Institute of Singapore and City of Hope National Medical Center. The basis for the Company was the landmark discovery of a new class of RNA inhibitors called DNMTs Interacting RNAs (DiRs) 1,2 . DiRs are capable of blocking aberrant DNA methylation at a single gene level reactivating previously hypermethylated genes – a key feature in cancer and genetic disorders. By reactivating specific genes, there is the opportunity to target the underlying cause of and potentially reverse specific intractable cancers and genetic conditions in adults, such as Myelodysplastic Syndrome (MDS) and, in children, such as Fragile X Syndrome. Aptadir’s proprietary platform can generate multiple DiRs for specific genes suppressed in cancer and genetic conditions, re-establishing the pathway functionality. The first programme, Aptadir Ce-49 is being developed in MDS and the aim is to enter the clinic by the end of 2025. Leading the management team is Giovanni Amabile who has been appointed Executive Chairman and acting CEO; he is also Entrepreneur in Residence of EXTEND. Previously, he was CEO at Enthera and before then, CSO at ADIENNE Pharma. He has a successful track record in raising seed and Series A funds, and for leading IND approvals, complex clinical trials and regulatory approvals in the US. Giovanni Amabile, Executive Chairman and CEO , said: “ Today represents the launch of Aptadir Therapeutics and is an exciting day for the founders and team. Aptadir’s business is based on real innovation - a landmark discovery of a new class of molecules which have the potential to be best-in-class therapeutics for intractable conditions. From data already generated, DiRs are highly selective, stable and non-toxic, and have the potential to be used across multiple indications. This is a really exciting new field and we are looking forward to pushing our first candidate forward into the clinic.” Aptadir has received $1.6m in pre-seed funding from the EXTEND initiative to optimize its lead asset, Aptadir Ce-49. The Company is the first to receive funding from EXTEND, which is the Italian National Technology Transfer Hub wholly dedicated to the biopharmaceutical sector for the development of new therapeutic approaches. The Hub was initiated by CDP Venture Capital SGR, and joint funded with co-investors, Angelini Ventures and Evotec SE. Its purpose is to develop translational drug discovery partnerships with highly renowned universities and research centers in Italy to accelerate their promising therapeutics for commercialization. Claudia Pingue, senior partner and head of the Technology Transfer Fund of CDP Venture Capital SGR , added: “ Aptadir is the first biotech company born from EXTEND, National Technology Transfer hub established on the initiative of CDP Venture Capital and funded with co-investment partners, Angelini Ventures and Evotec. EXTEND aims to develop high quality science coming from top Italian universities and to help build new start-ups that can develop that science for the benefit of future patients. Aptadir represents one of the best examples of where science innovation can create a new potential therapeutic for underserved conditions in adults and children, such as MDS and Fragile X Syndrome. We’ll be watching its progress with great interest.” Di Ruscio A et al 2013, Nature Esposito CL et al 2023, Nature Communication Notes to Editors About Aptadir Therapeutics Aptadir Therapeutics is a preclinical biotech company developing a new class of RNA therapeutics. The Company’s therapeutic focus is underserved intractable cancers and genetic conditions, including underserved intractable conditions in the oncology and rare diseases fields such as Myelodysplastic Syndrome and Fragile X Syndrome. The technology was developed and validated by a group of key opinion leaders in the field of RNA therapeutics based at three world class institutions: the Harvard Medical School, Cancer Science institute of Singapore, Italian CNR Institute and City of Hope National Medical Center. The platform is based on a landmark discovery of a new class of RNA inhibitors called DNMTs Interacting RNAs (DiRs) 1,2 . DiRs are capable of blocking aberrant DNA methylation at a single gene level reactivating previously hypermethylated genes – a key feature in cancer and genetic disorders. The first programme is developing a treatment for Myelodysplastic Neoplasms (MDS), a group of blood cancers that occur when immature blood cells in the bone marrow don't mature into healthy blood cells. Sufferers of MDS go on to develop acute myeloid leukaemia (AML). To find out more, please see: www.aptadir.com About EXTEND EXTEND is the Italian National Technology Transfer Hub (the Hub) wholly dedicated to the biopharmaceutical sector for the development of new therapeutic approaches and it was formed as an initiative of CDP Venture Capital to transform the results of this scientific research into new companies. Alongside CDP Venture Capital, the Hub is funded by co-investors, Evotec, which also acts as an entrepreneurial partner by supporting research groups along the path of scientific study up to the establishment of startups ready to raise capital on the market to start the clinical phase, and Angelini Ventures, the new Angelini Industries Group company operating in the VC sector with a focus on digital health and biotech. The scientific promoters of the initiative are IRSCC San Raffaele Hospital in Milan, the Universities of Milan, Florence, Modena and Reggio Emilia, Padua, Trento, La Sapienza in Rome, the regional research district of Puglia through H-Bio, and Human Technopole. To learn more, please visit: www.extend-tt.vc

Executive ChangeOligonucleotide

19 Dec 2022

·www.prnewswire.com

Global Cytotoxic Drugs and HPAPI Manufacturing Markets 2022-2035: Increasing Demand has Led to a Rise in the Number of HPAPIs in the Overall Pharmaceutical Development Pipeline

DUBLIN, Dec. 19, 2022 /PRNewswire/ -- The "Cytotoxic Drugs and HPAPI Manufacturing Market by Type of Product, Company Size, Scale of Operation, Type of Molecule, Type of Highly Potent Finished Dosage Form, and Key Geographies, Europe, Asia-Pacific and Rest of the World: Industry Trends and Global Forecasts, 2022-2035" report has been added to ResearchAndMarkets.com's offering. "Cytotoxic Drugs and HPAPI Manufacturing Market 2022-2035" report features an extensive study of the current market landscape and future potential of the HPAPI and cytotoxic drug manufacturing market, over the next decade. The study also features an in-depth analysis, highlighting the capabilities of various industry stakeholders engaged in this field. Aided by the ongoing advancements in clinical pharmacology and oncology research, as well as the rising demand for targeted therapies, high potency active pharmaceutical ingredients (HPAPIs) and cytotoxic drugs have emerged as one of the key areas of interest for researchers and drug developers worldwide. One of the key objectives of the report was to evaluate the current opportunity and the future growth potential of the HPAPI and cytotoxic drug manufacturing market over the coming years. We have provided an informed estimate on the likely evolution of the market in the short to mid-term and long term, for the period 2022-2035. The report also features a likely distribution of the current and forecasted opportunity across important parameters. In order to account for future uncertainties and to add robustness to our model, we have provided three market forecast scenarios, namely conservative, base and optimistic scenarios, representing different tracks of the industry's growth. Frequently Asked Questions What are the current opportunities within the HPAPI and cytotoxic drug market? The cytotoxic drugs and HPAPI manufacturing market is presently considered as one of the most powerful and dynamic sectors of the pharmaceutical industry. At present, more than 40% of the total number of drugs are highly potent in nature. Further, around 60% of the HPAPIs are being developed against oncological indications. Considering the upsurge in demand for novel anti-cancer therapeutics, including antibody-drug conjugates (ADCs), high potency compounds have generated significant interest among several researchers and industry stakeholders. What is the need for contract manufacturing organizations (CMOs) in the HPAPI and cytotoxic drug domain? The manufacturing of highly potent APIs and cytotoxic drugs requires an adequate working environment (to prevent cross contamination within multi-product assets), stringent manufacturing protocols (to comply with the established regulatory standards) and a trained workforce (to satisfactorily handle highly potent materials). In addition, it requires an expensive infrastructure, which is often complex to engineer, install and maintain. As a result, various companies rely on third party service providers to leverage their technologies for manufacturing highly potent and cytotoxic compounds and achieve greater operational flexibility. The inherent expertise of CMOs is believed to be capable of enabling reduction in the time-to-market a product and offer significant cost-benefits. What is the current market landscape and recent trends in the HPAPI and cytotoxic drug contract manufacturing domain? Presently, close to 145 companies have the required capabilities to offer HPAPI and cytotoxic drug manufacturing services across different scales of operation. In addition, several contract service providers are entering into strategic alliances in order to consolidate their presence in this field and enhance their existing capabilities to meet the growing demand for high potency molecules. It is worth mentioning that close to 50% of the expansion activities carried out in this market have been focused on improving the existing manufacturing facilities for highly potent molecules, through the addition of new structures and equipment. What are the key challenges faced by HPAPI and cytotoxic drug CMOs? The primary challenge faced during the manufacturing of highly potent APIs and cytotoxic drugs is related to limiting / altogether preventing cross-contamination of the highly potent molecule with other molecules being produced at the same site. Further, the lack of information related to safe exposure levels and toxicity of new chemical entities can risk the lives of workers and harm the environment. As a result, comprehensive management systems are required for safe handling and containment of highly potent molecules. In addition, proper cleaning techniques and waste treatment systems are extremely essential while producing such compounds. What are the key value drivers in the HPAPIs and cytotoxic drugs contract manufacturing market? The increasing demand for cytotoxic drugs has led to a rise in the number of HPAPIs in the overall pharmaceutical development pipeline. In order to cater to the growing demand for the production of such drug candidates, there is a requirement for safe manufacturing and containment technologies. Even though some pharmaceutical companies have made considerable investments to establish in-house capabilities, the capital-intensive nature and specialized containment requirements make the role of contract manufacturers crucial, specifically for small and mid-sized players. How is the revenue generation potential associated with cytotoxic drugs and HPAPI manufacturing market likely to evolve in the coming years? The cytotoxic drugs and HPAPI manufacturing market is projected to grow at a CAGR of approximately 12% in the coming years. Currently, in terms of type of molecule, the market is likely to be driven by highly potent small molecules. However, this trend is expected to change in the foreseen future, as the demand for highly potent biologics, such as cell and gene therapies, increases further. In addition, in terms of scale of operation, majority share of the contract service revenues is expected to be generated by commercial scale manufacturing operations. Specifically, in terms of geography, the cytotoxic drugs and HPAPI manufacturing market in Asia-Pacific is likely to grow at a relatively faster pace (~13%), in the long term. The report features detailed transcripts of interviews held with the following individuals: Antonella Mancuso and Maria Elena Guadagno (Vice President and Chief Operating Officer and Business Director, BSP Pharmaceuticals) Stacy McDonald and Jennifer L. Mitcham (Ex-Group Product Manager and Ex-Director-Business Development); Abul Khair (Business Development Associate, Catalent) Roberto Margarita (Business Development Director, CordenPharma) Klaus Hellerbrand (Managing Director, ProJect Pharmaceutics) Kevin Rosenthal (Ex-Business Head, Formulations and Finished Products, Alphora research) Mark Wright (Ex-Site Head, Grangemouth, Piramal Healthcare) Allison Vavala (Ex-Senior Manager, Business Development, Helsinn) Valentino Mandelli (Marketing and Sales Manager, Pharma, Cerbios-Pharma) Javier E. Aznarez Araiz (Ex-Business Development, Idifarma) COMPANY COMPETITIVENESS ANALYSIS HPAPI Contract Manufacturers: Company Competitiveness Analysis Highly Potent FDF Contract Manufacturers: Company Competitiveness Analysis HPAPI and Highly Potent FDF Contract Manufacturers: Company Competitiveness Analysis COMPANY PROFILES: HPAPI AND CYTOTOXIC DRUG MANUFACTURERS IN NORTH AMERICA AbbVie Cambrex Catalent Pfizer CentreOne Piramal Pharma Solutions COMPANY PROFILES: HPAPI AND CYTOTOXIC DRUG MANUFACTURERS IN EUROPE Abzena Aenova CARBOGEN AMCIS Hovione Lonza COMPANY PROFILES: HPAPI AND CYTOTOXIC DRUG MANUFACTURERS IN ASIA-PACIFIC AND REST OF THE WORLD Intas Pharmaceuticals Scinopharm STA Pharmaceutical (a WuXi AppTec company) Syngene Teva API LIST OF COMPANIES AND ORGANIZATIONS AbbVie Abzena ACES Pharma Adare Pharma Solutions ADC Biotechnology ADC Therapeutics ADIENNE Pharma and Biotech Aenova AGC Pharma Chemicals (A subsidiary of AGC Group) Agno Pharma AIMEDBIO Ajinomoto Bio-Pharma Services ALB Technology Alcami Alkermes Almac Alphora Research Altasciences Alvogen Amneal Pharmaceuticals AMPAC Fine Chemicals (A SK pharmteco company) Angelini Fine Chemicals (A subsidiary of Angelini Pharma) ANI Pharmaceuticals Antengene ANVI Pharma Aptuit (An Evotec company) Ardena Arevipharma (Acquired by Yonsung Group) Aspen API Astellas Pharma Astorg AstraZeneca Asymchem Laboratories Aurigene Pharmaceutical Services Avra Laboratories (Acquired by Advent International) Baxter BioPharma Solutions Bio-Synthesis BioTechnique BioVectra BiVictriX Therapeutics BOC Sciences Boehringer Ingelheim Bolt Biotherapeutics Boryung Pharmaceutical Bright Peak Therapeutics Bristol Myers Squibb BrYet Health Bryllan BSP Pharmaceuticals Bushu Pharmaceuticals Byondis Cambrex Capsugel (A Lonza company) CARBOGEN AMCIS (A Dishman Carbogen Amcis Group company) Catalent CellMosaic Celon Laboratories Cerbios-Pharma ChemCon ChemPartner CordenPharma CoreRx Creative Biolabs CritiTech Curia Custom Pharmaceutical Services (A part of Dr. Reddy's Laboratories) Cytopharma Daiichi Sankyo Dalton Pharma Services Dipharma Divi's Laboratories DOTTIKON EXCLUSIVE SYNTHESIS EirGen Pharma (Acquired by OPKO Health) Eisai Eli Lilly Enteris BioPharma (A subsidiary of SWK Holdings) Esteve Eurofins Scientific EVER Pharma Excella (Acquired by Fareva) Exelixis Fabbrica Italiana Sintetici Fareva Farmabios (A PharmaZell Group company) Farmhispania Femtogenix Fermion (A subsidiary of Orion) Flamma Formex (A subsidiary of Biotech Investment Group (BIG)) Formosa Laboratories Fresenius Kabi Frontida BioPharm (Acquired by Adare Pharma Solutions) Fujimoto Chemicals GeneQuantum Healthcare Genmab GENTEC PHARMACEUTICAL GROUP Gilead Sciences Glycotope Goodwin Biotechnology GP Pharm GTP Bioways Gustave Roussy Helsinn Advanced Synthesis Heraeus Hovione ICROM Idifarma (Acquired by Ardena) IDT Australia Iksuda Therapeutics ImmunoGen Indena Ind-Swift Laboratories Intas Pharmaceuticals Janssen Biotech Kodiak Sciences Kohlberg Kyongbo Pharmaceutical (A subsidiary of Chong Kun Dang Pharmaceutical) LakePharma Laurus Synthesis LegoChem Biosciences Levena Biopharma (A subsidiary of Sorrento Therapeutics) Lonza Lotus Pharmaceuticals Lubrizol Life Science MabPlex Mac-Chem (A NMS Group Company) Magle Chemoswed Malladi Drugs & Pharmaceuticals Mayne Pharma McSAF MEDICHEM Merck Mersana Therapeutics Metrics Contract Services MilliporeSigma Minafin Minakem (A subsidiary of Minafin) Mitsubishi Tanabe Pharma Mubadala MuseChem Natco Pharma Navrogen NBE-Therapeutics NerPharMa NJ Bio Normon Novartis Novasep Oasmia Pharmaceutical OEP Pharma Olon Oncotec Pharma Produktion Oxford BioTherapeutics Parabolic Drugs Patheon (Acquired by Thermo Fischer Scientific) PCI Pharma Services Pensatech Pharma Pfanstiehl Pfizer Pfizer CentreOne Pharmacare Premium Pharmaceutics International Pharmascience PharmaZell PILA PHARMA Piramal Pharma Solutions PrasFarma Procos (A subsidiary of CBC) ProJect Pharmaceutics Pyxis Oncology Quadira Biosciences Quotient Sciences Recipharm Recro Pharma Regis Technologies RemeGen Richman Chemical SafeBridge Consultants (Acquired by Trinity Consultants) Sai Life Sciences Sanofi Sartorius ScinoPharm Taiwan Seagen Seattle Genetics SEQENS (Acquired by SK Capital Partners) Shionogi Pharma Siegfried Sigma-Aldrich Fine Chemicals (SAFC) (a Sigma-Aldrich company) SK biotek SK Capital Societal CDMO Sofpromed Somatek SOTIO Biotech STA Pharmaceutical (A WuXi AppTec company) Stason Pharmaceuticals Sterling Pharma Solutions Sutro Biopharma Swedish Orphan Biovitrum (SOBI) SWK Holdings Symbiosis Pharmaceutical Services Synaffix Synbias Pharma Syngene Synthon TBD-Biodiscovery Tergus Pharma Teva API TRIO Pharmaceuticals Tubulis University of Goettingen UPM Pharmaceuticals Vectura Veranova VERAXA Biotech VUAB Pharma (A SAFICHEM company) VxP Pharma Wavelength Pharmaceuticals (A subsidiary of SEQENS) WuXi Biologics ZNZ Pharma For more information about this report visit Media Contact: Research and Markets Laura Wood, Senior Manager [email protected] For E.S.T Office Hours Call +1-917-300-0470 For U.S./CAN Toll Free Call +1-800-526-8630 For GMT Office Hours Call +353-1-416-8900 U.S. Fax: 646-607-1907 Fax (outside U.S.): +353-1-481-1716 Logo: SOURCE Research and Markets

Acquisition

12 Jul 2022

·www.prnewswire.com

Global Hospital Care Partnering 2015-2022: Key Deal Trends, Players and Financials

DUBLIN, July 12, 2022 /PRNewswire/ -- The "Global Hospital Care Partnering 2015-2022: Deal Trends, Players and Financials" report has been added to ResearchAndMarkets.com's offering. Global Hospital Care Partnering 2015 to 2022 provides the full collection of Hospital Care disease deals signed between the world's pharmaceutical and biotechnology companies since 2015. Trends in Hospital Care partnering deals Financial deal terms for headline, upfront and royalty by stage of development Hospital Care partnering agreement structure Hospital Care partnering contract documents Top Hospital Care deals by value Most active Hospital Care dealmakers Most of the deals included within the report occur when a licensee obtains a right or an option right to license a licensor's product or technology. More often these days these deals tend to be multi-component including both a collaborative R&D and a commercialization of outcomes element. The report takes readers through the comprehensive Hospital Care disease deal trends, key players and top deal values allowing the understanding of how, why and under what terms companies are currently entering Hospital Care deals. The report presents financial deal terms values for Hospital Care deals, where available listing by overall headline values, upfront payments, milestones and royalties enabling readers to analyse and benchmark the value of current deals. Global Hospital Care Partnering 2015 to 2022 includes: Trends in Hospital Care dealmaking in the biopharma industry since 2015 Access to headline, upfront, milestone and royalty data Access to hundreds of Hospital Care deal contract documents Comprehensive access to over 1200 Hospital Care deal records The leading Hospital Care deals by value since 2015 Most active Hospital Care dealmakers since 2015 Key Topics Covered: Executive Summary Chapter 1 - Introduction Chapter 2 - Trends in Hospital Care dealmaking 2.1. Introduction 2.2. Hospital Care partnering over the years 2.3. Hospital Care partnering by deal type 2.4. Hospital Care partnering by industry sector 2.5. Hospital Care partnering by stage of development 2.6. Hospital Care partnering by technology type 2.7. Hospital Care partnering by therapeutic indication Chapter 3 -Financial deal terms for Hospital Care partnering 3.1. Introduction 3.2. Disclosed financials terms for Hospital Care partnering 3.3. Hospital Care partnering headline values 3.4. Hospital Care deal upfront payments 3.5. Hospital Care deal milestone payments 3.6. Hospital Care royalty rates Chapter 4 - Leading Hospital Care deals and dealmakers 4.1. Introduction 4.2. Most active in Hospital Care partnering 4.3. List of most active dealmakers in Hospital Care 4.4. Top Hospital Care deals by value Chapter 5 - Hospital Care contract document directory 5.1. Introduction 5.2. Hospital Care partnering deals where contract document available Chapter 6 - Hospital Care dealmaking by therapeutic target 6.1. Introduction 6.2. Deals by Hospital Care therapeutic target Companies Mentioned 3D-Side 3D Systems 3M 3SBio 4WEB Medical 7 Hills Pharma 7D Surgical 11 Health and Technologies 111 A&E Medical AAP Implantate AG Aatru Medical Abbvie Abiomed Ab Medica Abram Scientific Absolute Antibody AbSorber Acacia Pharma Acacia Research Acare Medical Science Accelus Accenture Access Scientific Accord Healthcare Accuray AccuTec Blades Acelity Acell Acelrx Pharmaceuticals Acentrus Specialty Acerus ActLight Acuity Healthcare Acuna-Fombona AdaptHealth Adaptimmune ADAS 3D Medical Adeor Medical Adhezion Biomedical ADIENNE Pharma & Biotech Admedus Advanced Aesthetic Technologies Advanced Cooling Therapy Advanced Guidance Technologies Advanced IT Concepts Advanced Ultrasound Systems Advantage Medical Advanz Pharma AdventHealth Aerapy Aerobiotix Aesculap Aesthetic Management Partners Aesthetic Medical International Aethlon Medical Aetna Agadia Systems AgeX Therapeutics Agiliti AgNovos Healthcare Aguettant Aidoc Aiforia Technologies AirStrip Technologies AirXpanders Aitrics Akari Therapeutics Akers Biosciences Akumin ALASTIN Skincare Alfasigma Algeos AliMed AliveCor ALK-Abello Allegheny Technologies Allenex Allergan Allergan Aesthetics Alliance Medical Allied Centre for Medical Excellence Alliqua Biomedical Alloksys Life Sciences AlloSource Almirall Alnylam Pharmaceuticals Alpha Imaging Alphamedix Alphatec Spine Altan Pharma Altaris Capital Partners Altasciences Altitude International Alume Biosciences Alvarado Hospital Medical Center Alyzen Medical Physics Amag Pharmaceuticals Ambra Health Ambu Amedica Amedisys Amendia Amend Surgical American Academy of Orthopaedic Surgeons American College of Chest Physicians American Health Imaging American Medical Technologies American Society for Aesthetic Plastic Surgery American Well Amerinet AmerisourceBergen Amgen AMI Amicrobe AMNIOX Amomed Pharma Amplifire Amplyx Pharmaceuticals Ancestry Anelixis Therapeutics Anelto Angiodynamics Angion Biomedica Angsana Molecular & Diagnostics Anika Therapeutics Anita Tecnica ANP Technologies Antares Pharma Anthem Antibe Therapeutics Apex Physics Partners ApiFix Apollo Endosurgery Appalachian Regional Healthcare Apple Applied DNA Sciences Applimotion APR Medtech Aptevo Therapeutics Archer Capital Arch Therapeutics argenx Argon Medical Devices Aridea Solutions Aridis Pharmaceuticals Arjo Arkansas Childrens Hospital Armaghan Salamat Kish Armis Biopharma Armor Arsenal Medical Artegraft Arteriocyte Medical Systems Arthrex Arthrosurface ARxIUM Asahi Kasei Ascendum Ascension Ascension Saint Thomas Asensus Surgical ASICO AskAt Asklepios Group Aspen Surgical Products Assure Astarte Medical Astellas Pharma AstraZeneca Asys Athersys Atlas Lift Tech ATL Technology Atnahs Pharma Atos Medical Atricure For more information about this report visit Media Contact: Research and Markets Laura Wood, Senior Manager [email protected] For E.S.T Office Hours Call +1-917-300-0470 For U.S./CAN Toll Free Call +1-800-526-8630 For GMT Office Hours Call +353-1-416-8900 U.S. Fax: 646-607-1907 Fax (outside U.S.): +353-1-481-1716 Logo: SOURCE Research and Markets

Antibody

100 Deals associated with Adienne SA

100 Translational Medicine associated with Adienne SA

Corporation Tree

Boost your research with our corporation tree data.

view full example data

Pipeline

Pipeline Snapshot as of 07 Nov 2024

The statistics for drugs in the Pipeline is the current organization and its subsidiaries are counted as organizations,Early Phase 1 is incorporated into Phase 1, Phase 1/2 is incorporated into phase 2, and phase 2/3 is incorporated into phase 3

Preclinical

Approved

Other

Current Projects

Drug(Targets)	Indications	Global Highest Phase

Thiotepa ( DNA )	Mammary adenocarcinoma More	Approved
SAND-5 ( C5AR1 )	Hemolytic-Uremic Syndrome More	Preclinical
Begelomab ( DPP-4 )	Steroid Refractory Graft Versus Host Disease More	Discontinued
ADC 5311 ( DPP-4 )	Mesothelioma More	Pending
ADN-LYS(Adienne)	Gaucher Disease More	Pending

Deal

Boost your decision using our deal data.

view full example data

Translational Medicine

Boost your research with our translational medicine data.

view full example data

Profit

Explore the financial positions of over 360K organizations with Synapse.

view full example data

Grant & Funding(NIH)

Access more than 2 million grant and funding information to elevate your research journey.

view full example data

Investment

Gain insights on the latest company investments from start-ups to established corporations.

view full example data

Financing

Unearth financing trends to validate and advance investment opportunities.

view full example data

Chat with Hiro

Get started for free today!

Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.

Start your data trial now!

Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.

Bio

Bio Sequences Search & Analysis

Chemical

Chemical Structures Search & Analysis